Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy

Stephen Williams, Ravi Kacker, Graeme S. Steele, Jerome P. Richie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The presence of teratoma in the primary orchiectomy specimen creates controversies for subsequent management. Although predominant teratoma is less likely to metastasize, teratoma in the retroperitoneum may be less amenable to chemotherapy. In order to elucidate the issues about teratoma in the primary tumor, we reviewed differences between primary retroperitoneal lymph node dissection (P-RPLND) vs. post-chemotherapy RPLND (PC-RPLND) in patients with teratoma at orchiectomy. Materials and methods: Patients who had undergone RPLND at our institution from 2001 to 2008 were identified, and clinical charts reviewed. Eighty-three patients with teratoma at orchiectomy were identified and perioperative data were obtained. Results: Of the 83 patients with teratoma at orchiectomy who underwent RPLND, 44 (53%) and 39 (47%) underwent primary and PC-RPLND, respectively. Median follow-up was 1.4 years. Of the 83 patients with primary teratoma at orchiectomy, there were 7 (8%) patients with pure teratoma and 76 (92%) patients with mixed histology. Of the patients with mixed histology, 72 (87%) patients had embryonal carcinoma and 36 (43%) had LVI. There were 19 (43%) positive lymph nodes for P-RPLND, of which 13 (30%) contained teratoma. For the PC-RPLND group, 30 (77%) of lymph nodes were positive, of which 28 (72%) contained teratoma. There were 3 (4%) recurrences overall, all of which recurred in the PC-RPLND group. There were 11 (13%) perioperative complications total. There were no deaths in either group. Conclusions: Patients with teratoma at orchiectomy were associated with other high risk features and are at significant risk for metastatic disease. Patients with post-chemotherapy retroperitoneal findings are at significant risk for viable GCT and/or teratoma and should undergo PC-RPLND.

Original languageEnglish (US)
Pages (from-to)60-63
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Orchiectomy
Teratoma
Lymph Node Excision
Drug Therapy
Histology
Lymph Nodes
Embryonal Carcinoma

Keywords

  • Retroperitoneal lymph node dissection
  • Teratoma
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy. / Williams, Stephen; Kacker, Ravi; Steele, Graeme S.; Richie, Jerome P.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 1, 01.2012, p. 60-63.

Research output: Contribution to journalArticle

@article{03ce566ae5634d05a3b20d59e9e3a544,
title = "Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy",
abstract = "Objective: The presence of teratoma in the primary orchiectomy specimen creates controversies for subsequent management. Although predominant teratoma is less likely to metastasize, teratoma in the retroperitoneum may be less amenable to chemotherapy. In order to elucidate the issues about teratoma in the primary tumor, we reviewed differences between primary retroperitoneal lymph node dissection (P-RPLND) vs. post-chemotherapy RPLND (PC-RPLND) in patients with teratoma at orchiectomy. Materials and methods: Patients who had undergone RPLND at our institution from 2001 to 2008 were identified, and clinical charts reviewed. Eighty-three patients with teratoma at orchiectomy were identified and perioperative data were obtained. Results: Of the 83 patients with teratoma at orchiectomy who underwent RPLND, 44 (53{\%}) and 39 (47{\%}) underwent primary and PC-RPLND, respectively. Median follow-up was 1.4 years. Of the 83 patients with primary teratoma at orchiectomy, there were 7 (8{\%}) patients with pure teratoma and 76 (92{\%}) patients with mixed histology. Of the patients with mixed histology, 72 (87{\%}) patients had embryonal carcinoma and 36 (43{\%}) had LVI. There were 19 (43{\%}) positive lymph nodes for P-RPLND, of which 13 (30{\%}) contained teratoma. For the PC-RPLND group, 30 (77{\%}) of lymph nodes were positive, of which 28 (72{\%}) contained teratoma. There were 3 (4{\%}) recurrences overall, all of which recurred in the PC-RPLND group. There were 11 (13{\%}) perioperative complications total. There were no deaths in either group. Conclusions: Patients with teratoma at orchiectomy were associated with other high risk features and are at significant risk for metastatic disease. Patients with post-chemotherapy retroperitoneal findings are at significant risk for viable GCT and/or teratoma and should undergo PC-RPLND.",
keywords = "Retroperitoneal lymph node dissection, Teratoma, Testicular cancer",
author = "Stephen Williams and Ravi Kacker and Steele, {Graeme S.} and Richie, {Jerome P.}",
year = "2012",
month = "1",
doi = "10.1016/j.urolonc.2009.12.006",
language = "English (US)",
volume = "30",
pages = "60--63",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy

AU - Williams, Stephen

AU - Kacker, Ravi

AU - Steele, Graeme S.

AU - Richie, Jerome P.

PY - 2012/1

Y1 - 2012/1

N2 - Objective: The presence of teratoma in the primary orchiectomy specimen creates controversies for subsequent management. Although predominant teratoma is less likely to metastasize, teratoma in the retroperitoneum may be less amenable to chemotherapy. In order to elucidate the issues about teratoma in the primary tumor, we reviewed differences between primary retroperitoneal lymph node dissection (P-RPLND) vs. post-chemotherapy RPLND (PC-RPLND) in patients with teratoma at orchiectomy. Materials and methods: Patients who had undergone RPLND at our institution from 2001 to 2008 were identified, and clinical charts reviewed. Eighty-three patients with teratoma at orchiectomy were identified and perioperative data were obtained. Results: Of the 83 patients with teratoma at orchiectomy who underwent RPLND, 44 (53%) and 39 (47%) underwent primary and PC-RPLND, respectively. Median follow-up was 1.4 years. Of the 83 patients with primary teratoma at orchiectomy, there were 7 (8%) patients with pure teratoma and 76 (92%) patients with mixed histology. Of the patients with mixed histology, 72 (87%) patients had embryonal carcinoma and 36 (43%) had LVI. There were 19 (43%) positive lymph nodes for P-RPLND, of which 13 (30%) contained teratoma. For the PC-RPLND group, 30 (77%) of lymph nodes were positive, of which 28 (72%) contained teratoma. There were 3 (4%) recurrences overall, all of which recurred in the PC-RPLND group. There were 11 (13%) perioperative complications total. There were no deaths in either group. Conclusions: Patients with teratoma at orchiectomy were associated with other high risk features and are at significant risk for metastatic disease. Patients with post-chemotherapy retroperitoneal findings are at significant risk for viable GCT and/or teratoma and should undergo PC-RPLND.

AB - Objective: The presence of teratoma in the primary orchiectomy specimen creates controversies for subsequent management. Although predominant teratoma is less likely to metastasize, teratoma in the retroperitoneum may be less amenable to chemotherapy. In order to elucidate the issues about teratoma in the primary tumor, we reviewed differences between primary retroperitoneal lymph node dissection (P-RPLND) vs. post-chemotherapy RPLND (PC-RPLND) in patients with teratoma at orchiectomy. Materials and methods: Patients who had undergone RPLND at our institution from 2001 to 2008 were identified, and clinical charts reviewed. Eighty-three patients with teratoma at orchiectomy were identified and perioperative data were obtained. Results: Of the 83 patients with teratoma at orchiectomy who underwent RPLND, 44 (53%) and 39 (47%) underwent primary and PC-RPLND, respectively. Median follow-up was 1.4 years. Of the 83 patients with primary teratoma at orchiectomy, there were 7 (8%) patients with pure teratoma and 76 (92%) patients with mixed histology. Of the patients with mixed histology, 72 (87%) patients had embryonal carcinoma and 36 (43%) had LVI. There were 19 (43%) positive lymph nodes for P-RPLND, of which 13 (30%) contained teratoma. For the PC-RPLND group, 30 (77%) of lymph nodes were positive, of which 28 (72%) contained teratoma. There were 3 (4%) recurrences overall, all of which recurred in the PC-RPLND group. There were 11 (13%) perioperative complications total. There were no deaths in either group. Conclusions: Patients with teratoma at orchiectomy were associated with other high risk features and are at significant risk for metastatic disease. Patients with post-chemotherapy retroperitoneal findings are at significant risk for viable GCT and/or teratoma and should undergo PC-RPLND.

KW - Retroperitoneal lymph node dissection

KW - Teratoma

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84855695042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855695042&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.12.006

DO - 10.1016/j.urolonc.2009.12.006

M3 - Article

VL - 30

SP - 60

EP - 63

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -